Optical coherence tomography to monitor photodynamic therapy in pathological myopia

British Journal of Ophthalmology

Volumn 90, Issue 5, 2006, Pages 555-558

  García Layana, Alfredo ^a   Salinas Alaman A ^a   Maldonado, M J ^a   Sainz Gomez C ^a   Fernandez Hortelano A ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TIME;

ADULT; CHOROID; CHOROIDAL NEOVASCULARIZATION; EXTRACELLULAR FLUID; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDIES; RETINA; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 33646243554     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.085555     Document Type: Article

References (21)

1. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983;67:209-13.
2. Sperduto RD, Seigel D, Roberts J, et al. Prevalence of myopia in the United States. Arch Ophthalmol 1983;101:405-7.
3. Tano Y. Pathologic myopia: where are we now? Am J Ophthalmol 2002;134:645-60.
4. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic Therapy of Subfoveal Choroidal neovascularization in pathologic myopia with verteporfin. 1-Year results of a randomized clinical trial-VIP report No 1. Ophthalmology 2001;108:841-52.
5. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. 2-year Results of a randomized clinical trial-VIP Report No 3. Ophthalmology 2003;110:667-73.
6. Salinas-Alamán A, García-Layana A, Maldonado MJ, et al. Using optical coherence tomography to monitor photodynamic therapy in age related macular degeneration. Am J Ophthalmol 2005;140:23-8.
7. Sánchez-Tocino H, Álvarez-Vidal A, Maldonado MJ, et al. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 2002;43:1588-94.
8. Hee MR, Puliafito CA, Wang C, et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 1995;113:1019-29.
9. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 1996;103:1260-70.
10. Rogers AH, Martidis A, Greenberg PB, et al. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2002;134:566-76.
11. Costa RA, Farah ME, Cardillo JA, et al. Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina 2003;23:159-65.
12. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002;43:830-41.
13. Scupola A, Ventura L, Tiberti AC, et al. Histological findings of a surgically excised myopic choroidal neovascular membrane after photodynamic therapy. A case report. Graefes Arch Clin Exp Ophthalmol 2004;242:605-10.
14. Sahni J, Stanga P, Wong D, et al. Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularization secondary to age related macular degeneration: a cross sectional study. Br J Ophthalmol 2005;89:316-20.
15. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) study groups. Photodynamic therapy or subfoveal choroidal neovascularization with verteporfin. Fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP. Report No 2. Arch Ophthalmol 2003;121:1253-68.
16. Holz FG, Jorzik J, Schutt F, et al. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-Study). Ophthalmology 2003;110:400-5.
17. Kaiser RS, Berger JW, Williams GA, et al. Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration. Retina 2002;22:683-90.
18. Friedman SM, Margo CE. Choroidal neovascular membranes: reproducibility of angiographic interpretation. Am J Ophthalmol 2000;130:839-41.
19. Coscas G, Coscas F, Soubrane G. Monitoring the patient after treatment: angiographic aspects of recurrence and indications for retreatment. J Fr Ophtalmol 2004;27:81-92.
20. Yannuzzi LA, Rohrer KT, Tindel LJ, et al. Fluorescein angiography complication survey. Ophthalmology 1986;93:611-17.
21. Karhunen U, Raitta C, Kala R. Adverse reactions to fluorescein angiography. Acta Ophthalmol 1986;64:282-6.